{
  "@context": "https://schema.org",
  "@type": "ScientificKnowledge",
  "identifier": "vitamin-d-cardiovascular-prevention-2025",
  "context": {
    "primaryFocus": "Primary prevention of Major Adverse Cardiovascular Events (MACE) in the general population.",
    "reasoning": "Focus limited to large-scale, long-duration (4+ years) RCTs on cardiovascular outcomes to reflect the current standard of evidence.",
    "validityConfidence": 0.99
  },
  "claimBasis": [
    {
      "type": "meta-analysis",
      "citation": "Manson, J. E., et al. (2019). Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. The New England Journal of Medicine (VITAL Trial).",
      "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1809944"
    }
  ],
  "scenario": {
    "description": "Vitamin D supplementation reduces the risk of major adverse cardiovascular events (MACE) and all-cause cardiovascular mortality in non-deficient adults.",
    "domain": "scientific",
    "parameters": {
      "population": "Community-dwelling adults (men aged 50+ and women aged 55+)",
      "intervention": "Vitamin D3 (2000 IU/day)",
      "comparator": "Placebo",
      "outcome": "MACE (Myocardial infarction, stroke, cardiovascular death, or coronary revascularization)",
      "timeframe": "Median 5.3 years follow-up"
    }
  },
  "conclusion": {
    "claim": "Vitamin D supplementation provides no clinically significant benefit in reducing major adverse cardiovascular events (MACE) or all-cause cardiovascular mortality in the general population.",
    "confidence": 0.4,
    "confidenceInterval": [
      0.3,
      0.5
    ],
    "factuality": "False",
    "outcome": {
      "result": "Recent large RCTs showed no statistical difference in MACE between the supplementation and placebo groups. Any observed association is likely observational confounding."
    }
  },
  "bayesianAnalysis": {
    "prior": {
      "confidence": 0.6,
      "basis": "Base rate: 60% of nutrient supplements show initial positive results (observational/small trials) before large RCTs.",
      "source": "Adapted from Fortmann et al. (2013) meta-analysis on supplements",
      "method": "base-rate"
    },
    "evidence": [
      {
        "factor": "Primary outcome results from large, high-quality RCTs (like VITAL) showed no significant benefit for MACE or stroke, resulting in only **Weak/Anecdotal** evidence against the original hypothesis.",
        "increases": false,
        "posteriorAfter": 0.4,
        "bayesFactor": 0.444,
        "probabilityProvenance": {
          "P_E_given_H": 0.4,
          "P_E_given_H_reasoning": "Probability of observing a null effect in large RCTs, even if a small true effect exists (due to insufficient follow-up or effect size being too small to be meaningful).",
          "P_E_given_not_H": 0.9,
          "P_E_given_not_H_reasoning": "High probability of observing a null effect in large RCTs if the true effect is null (high statistical power to rule out effect).",
          "BF": 0.444,
          "calculation": "0.4 / 0.9 = 0.444 (for hypothesis H). The inverse is 2.25. This is categorized as **Weak/Anecdotal** (BF 1-3) against H.",
          "evidenceGrade": "Grade A"
        }
      }
    ],
    "posterior": 0.4,
    "howToChangeMyMind": [
      "New large RCT (N>30,000) focused specifically on **deficient** populations shows a 20%+ reduction in MACE → confidence rises to ~0.75",
      "Meta-analysis pooling all RCTs shows a strong signal for secondary outcomes (e.g., atrial fibrillation) → confidence for specific sub-claim rises to ~0.60"
    ]
  },
  "metadata": {
    "createdDate": "2025-11-06T12:00:00Z",
    "lastUpdated": "2025-11-06T12:00:00Z",
    "version": "1.2.0",
    "author": "Legis Ledger Fact-Check Pilot",
    "funnelPosition": "approaching-narrow",
    "funnelJustification": "Large-scale RCTs have failed to find a positive effect, moving the claim away from the middle-funnel of uncertainty toward a consensus of 'null' or 'false'.",
    "gitCommit": "cardio-v1.2.0-20251106",
    "relatedClaims": [
      {
        "identifier": "vitamin-d-bone-health-2025",
        "claim": "Vitamin D improves bone health and reduces fractures.",
        "confidence": 0.9,
        "funnelPosition": "narrow-end-canonical",
        "note": "Established Canonical Knowledge"
      },
      {
        "identifier": "vitamin-d-dementia-prevention-2025",
        "claim": "Vitamin D supplementation to prevent dementia is uncertain.",
        "confidence": 0.5,
        "funnelPosition": "middle-funnel",
        "note": "Uncertainty (RCT evidence is mixed/insufficient)"
      },
      {
        "identifier": "vitamin-d-cardiovascular-prevention-2025",
        "claim": "Vitamin D reduces cardiovascular risk and mortality.",
        "confidence": 0.4,
        "funnelPosition": "approaching-narrow",
        "note": "Current Abstract (Consensus of Null/False)"
      }
    ]
  },
  "sources": [
    {
      "type": "meta-analysis",
      "citation": "Manson, J. E., et al. (2019). Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. The New England Journal of Medicine (VITAL Trial).",
      "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1809944"
    }
  ],
  "disclaimer": {
    "nature": "educational",
    "domainSpecific": {
      "notMedicalAdvice": true
    },
    "provenanceAndLimitations": {
      "submittedBy": "Independent educational project",
      "notSubmittedByAuthority": "NOT submitted by FDA or NIH",
      "potentialBiases": [
        "Analysis may be biased toward published consensus of null effect"
      ],
      "howToVerify": [
        "Review primary results of the VITAL trial and follow-up meta-analyses",
        "Consult physician"
      ]
    }
  }
}